logo
logo

Protai Adds $12 Million To Seed Round - Bringing The Total To $20 Million - To Build An Oncology Drug Discovery Pipeline

Mar 15, 2023over 2 years ago

Amount Raised

$12 Million

Round Type

seed

Tel AvivArtificial IntelligenceData And AnalyticsSoftware

Investors

Maj Invest Equity FundPitango Health TechGrove Ventures

Description

Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced that it has added $12 million to its seed round, bringing the total amount to $20M. The round includes existing investors Grove Ventures and Pitango HealthTech and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai's oncology drug discovery pipeline, expand data acquisition as well as increase its discovery activities via pharma partnerships.

Company Information

Company

Protai

Location

Tel Aviv, Tel Aviv District, Israel

About

Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech